- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target | 1 | Investing.com | ||
| Mo | OKYO Pharma appoints Robert Dempsey as new CEO | 1 | Investing.com | ||
| Mo | OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO | 2 | RTTNews | ||
| Mo | OKYO Pharma ernennt Robert J. Dempsey zum neuen Chief Executive Officer | 1 | Investing.com Deutsch | ||
| Mo | OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer | 157 | GlobeNewswire (Europe) | Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on... ► Artikel lesen | |
| Mo | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.12.25 | OKYO Pharma: Management läutet Eröffnungsglocke der NASDAQ in New York | 2 | Investing.com Deutsch | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | OKYO Pharma to Ring the Opening Bell at Nasdaq | 273 | GlobeNewswire (Europe) | LONDON and NEW YORK, Dec. 19, 2025), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and... ► Artikel lesen | |
| 19.12.25 | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.12.25 | Okyo Pharma: Executive Chairman stockt Beteiligung auf | 3 | Investing.com Deutsch | ||
| 15.12.25 | Okyo Pharma executive chairman increases stake in company | 3 | Investing.com | ||
| 15.12.25 | OKYO Pharma Announces Chairman and Founder Acquires Shares | 270 | GlobeNewswire (Europe) | LONDON and NEW YORK, Dec. 15, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 11.12.25 | Studie zu Hornhautschmerzen: Urcosimod von OKYO Pharma deutet auf Nervenregeneration hin | 2 | Investing.com Deutsch | ||
| 11.12.25 | OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain | 321 | GlobeNewswire (Europe) | Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod... ► Artikel lesen | |
| 11.12.25 | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.12.25 | B.Riley initiates coverage on OKYO Pharma stock with Buy rating | 1 | Investing.com | ||
| 08.12.25 | B.Riley startet Coverage für OKYO Pharma mit Kaufempfehlung und hohem Kursziel | 2 | Investing.com Deutsch | ||
| 03.12.25 | OKYO Pharma: Dem Chairman nahestehendes Unternehmen kauft Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| 03.12.25 | OKYO Pharma Announces Chairman and Founder Acquires Shares | 251 | GlobeNewswire (Europe) | LONDON and NEW YORK, Dec. 03, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 03.12.25 | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 605,00 | -1,05 % | Palo Alto, Capital One Financial, IDEXX Laboratories And More: CNBC's 'Final Trades' | ||
| BIOXCEL THERAPEUTICS | 1,742 | +1,40 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,034 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,510 | +0,57 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| ANAVEX LIFE SCIENCES | 3,533 | -3,50 % | Anavex Life Sciences Corp.: Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments... ► Artikel lesen | |
| CELLAVISION | 14,380 | 0,00 % | CellaVision: CellaVision appoints Monica Jönsson as new CFO | CellaVision announces today the appointment of Monica Jönsson as Chief Financial Officer (CFO). Monica is currently Interim CFO at CellaVision. Monica Jönsson brings extensive experience from leading... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 3,500 | +1,16 % | Precision BioSciences: Sind das jetzt Super-Schnäppchen? | Die Aktie von Precision BioSciences ist eines der wenigen Biotech-Papiere, die in diesem Jahr keinen Höhenflug erlebten. Im Gegenteil: Die Aktie hat ohne schlechte Unternehmensnews in den letzten Monaten... ► Artikel lesen | |
| ZYMEWORKS | 20,000 | +0,50 % | Zymeworks Inc.: Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit | Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the... ► Artikel lesen | |
| VTV THERAPEUTICS | 35,800 | +0,56 % | This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| QUOIN PHARMACEUTICALS | 10,800 | -4,00 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,070 | +2,52 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| NUVATION BIO | 8,450 | 0,00 % | Nuvation Bio: UBS nimmt Coverage mit "Neutral"-Rating auf | ||
| MIRA PHARMACEUTICALS | 1,280 | +0,79 % | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,130 | +0,89 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment... ► Artikel lesen | |
| ONCONETIX | 1,720 | -6,01 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.